"Combining PRIMARY and PI-RADS scores could be a game-changer in how prostate cancer is diagnosed," says Louise Emmett, MBChB, FRACP, MD.

The grants will support research evaluating ATAD2 in advanced prostate cancer and 6MP in hereditary leiomyomatosis and renal cell cancer.

New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

"It clearly shows that blocking HIF-2α is a meaningful way of interacting with disease biology in clear cell renal cell carcinoma," says Eric Jonasch, MD.

Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy ...

“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a ...

"But for physicians considering chemotherapy for which there is equipoise, the Decipher test could be used to swing the decision one way or the other," says Gerhardt Attard, MD, PhD, FRCP. In this ...

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while ...

“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

“We already have very effective ARPIs available around the world, and this will add to those therapeutic options to try to tailor patients based on their needs [and] their particular profiles,” says ...

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.